Telix Pharmaceuticals Files Q1 2026 Business Update
Ticker: TLX · Form: 6-K · Filed: Apr 7, 2026 · CIK: 0002007191
| Field | Detail |
|---|---|
| Company | Telix Pharmaceuticals Ltd (TLX) |
| Form Type | 6-K |
| Filed Date | Apr 7, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: quarterly-report, business-update, foreign-issuer
TL;DR
Telix dropped its Q1 2026 business update on 4/7/26 - check EX-99.1 for deets.
AI Summary
Telix Pharmaceuticals Ltd. filed a 6-K report on April 7, 2026, for the period ending March 31, 2026. The filing includes a business update for the first quarter of 2026, with detailed financial and operational information presented in an attached exhibit (EX-99.1). The report is from a foreign issuer and contains graphic elements.
Why It Matters
This filing provides investors with a quarterly update on Telix Pharmaceuticals' business performance and financial standing, crucial for assessing the company's progress and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly filing (6-K) providing business updates, not indicating any immediate or significant new risks.
Key Players & Entities
- Telix Pharmaceuticals Ltd (company) — Filer
- 0002007191 (company) — CIK number
- 2026-04-07 (date) — Filing Date
- 2026-03-31 (date) — Period of Report
- EX-99.1 (document) — Business update exhibit
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report business updates for Telix Pharmaceuticals Ltd. for the period ending March 31, 2026.
When was this filing accepted by the SEC?
This filing was accepted by the SEC on April 7, 2026.
What is the accession number for this filing?
The SEC accession number for this filing is 0001628280-26-023982.
Which exhibit contains the Q1 2026 business update?
Exhibit EX-99.1 contains the Q1 2026 business update.
What is the CIK number for Telix Pharmaceuticals Ltd?
The CIK number for Telix Pharmaceuticals Ltd is 0002007191.
Filing Stats: 200 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2026-04-07 06:27:27
Filing Documents
- telix-6kforq1businessrelea.htm (6-K) — 20KB
- q1businessupdate.htm (EX-99.1) — 164KB
- image_01.jpg (GRAPHIC) — 74KB
- 0001628280-26-023982.txt ( ) — 287KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Telix Pharmaceuticals Limited Date April 7, 2026 By s Christian Krautkramer Name Christian Krautkramer Title Group General Counsel